Article ID: b16-00898
Alzheimer’s disease (AD) is a most serious age-related neurodegenerative disorder accompanied with significant memory impairments in this world. Recently, microRNAs have been reported to be invlolved in the pathophysiology of AD. Previous studies have shown that miR-206 is implicated in the pathogenesis of AD via suppressing the expression of BDNF in the brain. Here, we examined the miR-206-3p and miR-206-5p expression in the hippocampus and cortex of APP/PS1 transgenic mice treated with donepezil, a drug approved for treating AD in clinic. We found that the expression of miR-206-3p was significantly up-regulated in the hippocampus and cortex of APP/PS1 mice, while donepezil administration significantly reversed this dysfunction. In addition, enhancing the miR-206-3p level by the usage of AgomiR-206-3p significantly attenuated the anti-dementia effects of donepezil in APP/PS1 mice. Together, these results suggested that miR-206-3p is involved in the anti-dementia effects of donepezil, and could be a novel pharmacological target for treating AD.
